Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

IXJ vs. ETHSX: which is better?

Bottom line

IXJ vs ETHSX: the short answer

IXJ (iShares Global Healthcare ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 74% by weight.

But IXJ is far broader, holding 124 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.

IXJ is cheaper at 0.38% vs 1.18% — a difference of $80 a year per $10,000 invested.

Over five years, IXJ returned +6.4% a year vs +5.3% for ETHSX (reporting dates differ).

ETHSX has a front-end sales load of up to 5.25%; the other does not.

Updated Nov 19, 2026

IXJ vs ETHSX side by side

IXJETHSX
TypeETFMutual fund
Fund familyiSharesMorgan Stanley
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.38%1.18%
Annual cost per $10k$38$118
10-yr cost on $10k (prospectus)$480$1,911
Max front loadNone5.25%
12b-1 fee0%0.25%
1-yr return+14.9%−1.9%
5-yr return (annualized)+6.4%+5.3%
10-yr return (annualized)+8.2%+6.4%
Best quarter+13.6%+14.2%
Worst quarter−11.8%−12.1%
Net assets (fund)$3.8B$757.9M
Number of holdings12442
Portfolio turnover2%3%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearIXJETHSXDifference
2024+0.6%+3.5%−2.9%
2023+3.5%+5.7%−2.2%
2022−4.7%−9.4%+4.7%
2021+19.5%+22.1%−2.6%
2020+12.5%+13.0%−0.6%
2019+23.4%+26.0%−2.6%
2018+2.9%+6.0%−3.1%
2017+20.3%+16.2%+4.1%
2016−6.2%−14.9%+8.7%
2015+5.9%+8.4%−2.5%

Source: Fund prospectus bar charts

Holdings overlap

17 of IXJ's top 25 holdings also appear in ETHSX's top 25.

Shared top holdings
HoldingIXJETHSX
Eli Lilly And Company10.93%12.47%
Johnson & Johnson7.04%6.45%
Abbvie Inc.5.12%6.46%
Unitedhealth Group Incorporated4.40%5.49%
Merck & Co., Inc.4.12%5.08%
Astrazeneca Plc3.76%6.24%
Roche Holding AG3.75%5.44%
Novartis AG3.71%1.65%
Thermo Fisher Scientific Incorporated2.42%2.79%
Abbott Laboratories2.05%1.65%
Gilead Sciences, Inc.2.04%3.34%
Novo Nordisk A/s1.99%1.71%
Intuitive Surgical, Inc.1.83%2.72%
Vertex Pharmaceuticals Incorporated1.64%3.38%
Bristol-myers Squibb Company1.53%4.25%

Source: SEC Form N-PORT

IXJ top 10

  1. Eli Lilly And Company — 10.93%
  2. Johnson & Johnson — 7.04%
  3. Abbvie Inc. — 5.12%
  4. Unitedhealth Group Incorporated — 4.40%
  5. Merck & Co., Inc. — 4.12%
  6. Astrazeneca Plc — 3.76%
  7. Roche Holding AG — 3.75%
  8. Novartis AG — 3.71%
  9. Amgen Inc. — 2.54%
  10. Thermo Fisher Scientific Incorporated — 2.42%

ETHSX top 10

  1. Eli Lilly & Co — 12.47%
  2. AbbVie Inc — 6.46%
  3. Johnson & Johnson — 6.45%
  4. AstraZeneca PLC — 6.24%
  5. UnitedHealth Group Inc — 5.49%
  6. Roche Holding AG — 5.44%
  7. Merck & Co Inc — 5.08%
  8. Bristol-Myers Squibb Co — 4.25%
  9. Vertex Pharmaceuticals Inc — 3.38%
  10. Gilead Sciences Inc — 3.34%

FAQ

What is the difference between IXJ and ETHSX?
IXJ (iShares Global Healthcare ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 74% by weight. But IXJ is far broader, holding 124 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
Which is cheaper, IXJ or ETHSX?
IXJ has the lower expense ratio (0.38%).
Should I own both IXJ and ETHSX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.